Our results extend these findings to T1D and demonstrate a specific effect of iLD-IL-2 treatment in reducing pathogenic IL-21-producing CXCR5+ TFH cells as well as IL-21-producing CXCR5low T cells. This evidence concerns the gene CXCR5 and type 1 diabetes mellitus.